Stronger Opening
Stocks appear set to open higher
Tuesday.
Biotech company Cryolife
(
CRY |
Quote |
Chart |
News |
PowerRating) has
received FDA Pre-Market Approval on CRY’s Bio Glue surgical adhesive.
According to a report in the Wall
Street Journal, Microsoft
(
MSFT |
Quote |
Chart |
News |
PowerRating) has offered to back Cox Communications
(
COX |
Quote |
Chart |
News |
PowerRating) and Comcast
(
CMCSK |
Quote |
Chart |
News |
PowerRating) in an attempt to block AOL Time Warner’s
(
AOL |
Quote |
Chart |
News |
PowerRating)
purchase of AT&T’s
(
T |
Quote |
Chart |
News |
PowerRating) Broadband unit.
Banc of America Securities upgraded
MedImmune
(
MEDI |
Quote |
Chart |
News |
PowerRating) from Market Perform to Buy and put a price target on the
company at $53.
Myriad Genetics
(
MYGN |
Quote |
Chart |
News |
PowerRating) announced
that it has entered a new partnership with Lab Corp.
(
LH |
Quote |
Chart |
News |
PowerRating) to make its products
available to primary care physicians.
A warning letter which was issued to
Johnson & Johnson
(
JNJ |
Quote |
Chart |
News |
PowerRating) by European regulatory authorities is viewed as
a positive for Amgen
(
AMGN |
Quote |
Chart |
News |
PowerRating) psychologically according to Morgan Stanley,
while Bear Stearns sees it as a significant catalyst for AMGN and reiterated its
Buy rating on the biotech.
Morgan Stanley downgraded Quest
Software
(
QSFT |
Quote |
Chart |
News |
PowerRating) from Outperform to Neutral due to its valuation.
Merrill Lynch has added Home Depot
(
HD |
Quote |
Chart |
News |
PowerRating)
to its Focus List and put a price target of $58 on the do-it-yourself home
improvement store.
Reader’s Digest
(
RDA |
Quote |
Chart |
News |
PowerRating) was upgraded
by Merrill Lynch from Accumulate to Long Term Buy.
Limited Too
(
TOO |
Quote |
Chart |
News |
PowerRating) was upgraded by
Bear Stearns from Attractive to Buy, one day after UBS Warburg downgraded the
retailer.
CV Therapeutics
(
CVTX |
Quote |
Chart |
News |
PowerRating) priced 2.5
million shares at $52.50 in a follow-on offering.